UY27992A1 - Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht - Google Patents

Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht

Info

Publication number
UY27992A1
UY27992A1 UY27992A UY27992A UY27992A1 UY 27992 A1 UY27992 A1 UY 27992A1 UY 27992 A UY27992 A UY 27992A UY 27992 A UY27992 A UY 27992A UY 27992 A1 UY27992 A1 UY 27992A1
Authority
UY
Uruguay
Prior art keywords
compounds
compound
imidazopiridine
pharmaceutically acceptable
substituted piperidinyl
Prior art date
Application number
UY27992A
Other languages
English (en)
Inventor
Yasuhiro Katsu
Kon-I Kana
Hirohide Noguchi
Chikara Uchida
Mikio Morita
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32030864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27992(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of UY27992A1 publication Critical patent/UY27992A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención proporciona un compuesto de fórmula (I): o una amida farmacéuticamente aceptable de dicho compuesto, o un éster farmacéuticamente aceptable de dicho compuesto, y sus sales farmacéuticamente aceptables. Estos compuestos tienen actividad de unión al receptor 5-HT4,y por tanto son útiles para tratar la enfermedad de reflujo gastroesofágico, dispepsia no ulcerosa, dispepsia funcional, síndrome del intestino irritable o similares, en un mamífero, especialmente seres humanos. Esta invención también proporciona una composición farmacéutica que comprende el compuesto anterior.
UY27992A 2002-09-20 2003-09-19 Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht UY27992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41242602P 2002-09-20 2002-09-20

Publications (1)

Publication Number Publication Date
UY27992A1 true UY27992A1 (es) 2004-04-30

Family

ID=32030864

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27992A UY27992A1 (es) 2002-09-20 2003-09-19 Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht

Country Status (13)

Country Link
US (1) US6951867B2 (es)
EP (1) EP1543004A1 (es)
JP (1) JP2006502180A (es)
AR (1) AR041303A1 (es)
AU (1) AU2003259482A1 (es)
BR (1) BR0314584A (es)
CA (1) CA2499494A1 (es)
GT (1) GT200300208A (es)
MX (1) MXPA05003065A (es)
PA (1) PA8582901A1 (es)
TW (1) TW200406412A (es)
UY (1) UY27992A1 (es)
WO (1) WO2004026868A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094418A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
EP1689742B1 (en) * 2003-11-24 2010-03-17 Pfizer, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EA200801608A1 (ru) * 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
EP1807423B1 (en) 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
JP5159317B2 (ja) 2004-12-22 2013-03-06 セラヴァンス， インコーポレーテッド インダゾール−カルボキサミド化合物
US7446114B2 (en) 2005-03-02 2008-11-04 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2421237T7 (es) * 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010091411A1 (en) * 2009-02-09 2010-08-12 Glaxosmithkline Llc Piperidinyl cyclic amido antiviral agents
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
BR112012010648A2 (pt) 2009-11-06 2020-12-01 Sk Biopharmaceuticals Co., Ltd. uso de compostos na preparação de composições farmacêuticas para tratar síndrome de fibromialgia e composição farmacêutica
MX2012005258A (es) 2009-11-06 2012-06-19 Sk Biopharmaceuticals Co Ltd El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad.
MX343165B (es) * 2010-02-12 2016-10-26 Raqualia Pharma Inc Agonistas del receptor 5-ht4 para el tratamiento de demencia.
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
MX2017005940A (es) 2014-11-06 2018-01-11 Lysosomal Therapeutics Inc Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
KR20180133461A (ko) 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3452455A4 (en) * 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
GB2589573A (en) 2019-12-02 2021-06-09 Caterpillar Inc Bucket actuator assembly with resilient bump stop

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
FR2646894B3 (fr) * 1989-05-11 1991-07-12 Sleever Int Procede pour controler la temperature dans un four-tunnel ouvert a ses deux extremites, et dispositif pour la mise en oeuvre du procede
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5219850A (en) 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5196547A (en) 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
GB9221468D0 (en) * 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
AU3192295A (en) 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
WO1997027852A1 (en) 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001519766A (ja) 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
KR20060120715A (ko) 1998-03-31 2006-11-27 아카디아 파마슈티칼스 인코포레이티드 무스카린 수용체에 대해 활성을 갖는 화합물
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
MXPA04002495A (es) * 2001-10-22 2004-05-31 Pfizer Compuestos de imidazopiridin como moduladores del receptor 5-ht4.
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators

Also Published As

Publication number Publication date
TW200406412A (en) 2004-05-01
AR041303A1 (es) 2005-05-11
GT200300208A (es) 2004-05-20
CA2499494A1 (en) 2004-04-01
BR0314584A (pt) 2005-08-09
AU2003259482A1 (en) 2004-04-08
US20040127514A1 (en) 2004-07-01
EP1543004A1 (en) 2005-06-22
WO2004026868A1 (en) 2004-04-01
US6951867B2 (en) 2005-10-04
MXPA05003065A (es) 2005-05-27
JP2006502180A (ja) 2006-01-19
PA8582901A1 (es) 2004-05-26

Similar Documents

Publication Publication Date Title
UY27992A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht
UY28496A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
AR036906A1 (es) Compuestos de imidazopiridin como moduladores del receptor 5-ht4
DOP2003000703A (es) Compuestos de imidazopiradina como agonistas del receptor 5-ht4
NO20073183L (no) Tetrahydrokinolinanalgoer som muskariniske agonister
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
DE60318177D1 (de) Rho-kinase inhibitoren
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
UY29322A1 (es) Inhibidores de cxcr2
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
NO323467B1 (no) Farmasoytisk sammensetning som omfatter antihypertensivt middel og en VEGF-reseptortyrosinkinaseinhibitor, et testsett som omfatter middelet og inhibitorene og anvendelse av dem for fremstilling av et medikament
DE602005021696D1 (de) Indazolcarbonsäureamidverbindungen
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
CY1112826T1 (el) [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
CL2011001839A1 (es) Compuestos derivados de tiadiazoles y oxadiazoles, inhibidores de la biosintesis de trigliceridos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y/o la prevencion de obesidad, dislipidemia, afecciones de alteracion de la glucosa en ayunas, diabetes de tipo 2, entre otras.
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126